LUC00118I2 - - Google Patents

Download PDF

Info

Publication number
LUC00118I2
LUC00118I2 LU00118C LUC00118C LUC00118I2 LU C00118 I2 LUC00118 I2 LU C00118I2 LU 00118 C LU00118 C LU 00118C LU C00118 C LUC00118 C LU C00118C LU C00118 I2 LUC00118 I2 LU C00118I2
Authority
LU
Luxembourg
Application number
LU00118C
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00118(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of LUC00118I1 publication Critical patent/LUC00118I1/fr
Publication of LUC00118I2 publication Critical patent/LUC00118I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
LU00118C 2004-11-12 2019-05-08 LUC00118I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (fr) 2004-11-12 2005-11-14 Modification du facteur fviii en fonction du site

Publications (2)

Publication Number Publication Date
LUC00118I1 LUC00118I1 (fr) 2019-05-13
LUC00118I2 true LUC00118I2 (fr) 2019-12-27

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00118C LUC00118I2 (fr) 2004-11-12 2019-05-08

Country Status (32)

Country Link
US (4) US7632921B2 (fr)
EP (9) EP3243833B1 (fr)
JP (5) JP2008524117A (fr)
KR (7) KR101654011B1 (fr)
CN (6) CN103102406B (fr)
AU (1) AU2005304622B2 (fr)
BR (2) BR122016022033B8 (fr)
CA (1) CA2586379C (fr)
CY (3) CY1119292T1 (fr)
DK (3) DK1824988T3 (fr)
ES (4) ES2821832T3 (fr)
FR (1) FR19C1031I2 (fr)
HK (3) HK1117875A1 (fr)
HN (1) HN2007015683A (fr)
HR (2) HRP20180481B1 (fr)
HU (5) HUE059193T2 (fr)
IL (3) IL182903A (fr)
LT (5) LT2363414T (fr)
LU (1) LUC00118I2 (fr)
MA (1) MA29663B1 (fr)
MX (2) MX350293B (fr)
NL (1) NL300989I2 (fr)
NO (3) NO345800B1 (fr)
NZ (1) NZ555032A (fr)
PH (2) PH12014500352A1 (fr)
PL (3) PL2371856T3 (fr)
PT (4) PT2371856T (fr)
RU (1) RU2423380C2 (fr)
SI (4) SI2363414T1 (fr)
UA (1) UA95225C2 (fr)
WO (1) WO2006053299A2 (fr)
ZA (1) ZA200703696B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615945B1 (fr) 2003-04-09 2011-09-28 BioGeneriX AG Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
MXPA06015234A (es) * 2004-06-30 2007-11-22 Nektar Therapeutics Al Corp Conjugados de fraccion polimero-factor ix.
EP1771066A2 (fr) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon glp-1
EP1814573B1 (fr) 2004-10-29 2016-03-09 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
PL2371856T3 (pl) 2004-11-12 2022-08-22 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
MX2007008229A (es) 2005-01-10 2007-09-11 Neose Technologies Inc Factor estimulador de colonias de granulocitos glicopegilado.
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
MX2008014685A (es) * 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
EP2170919B8 (fr) 2007-06-12 2016-01-20 ratiopharm GmbH Procédé amélioré pour la production de sucres de nucléotide
CA2704234A1 (fr) * 2007-11-09 2009-05-14 Baxter International Inc. Facteur viii et facteur de von willebrand recombines modifies et procede d'utilisation
DK2257311T3 (da) * 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
KR20110022604A (ko) 2008-05-16 2011-03-07 바이엘 헬스케어 엘엘씨 표적화 응고 인자 및 그의 사용 방법
CA2726942A1 (fr) * 2008-06-04 2009-12-10 Bayer Healthcare Llc Muteines du facteur viii pour le traitement de la maladie de von willebrand
RU2528855C2 (ru) 2008-06-24 2014-09-20 Цсл Беринг Гмбх Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения
WO2010019263A2 (fr) * 2008-08-15 2010-02-18 Genzyme Corporation Produits de construction de flt soluble pour traiter des cancers
HUE039906T2 (hu) * 2008-10-17 2019-02-28 Baxalta GmbH Alacsony fokú vízben oldható polimer tartalmú módosított vérfaktorok
WO2010062768A1 (fr) * 2008-11-03 2010-06-03 Bayer Healthcare Llc Procédé de traitement de l'hémophilie
CA2744340A1 (fr) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Procede de determination d'activite de facteur de coagulation sanguine pegyle dans un essai de temps de thromboplastine partielle activee a base de silice
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
MX2011008094A (es) 2009-02-03 2012-02-13 Amunix Operating Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
JP2012518029A (ja) * 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
CN102369209B (zh) * 2009-03-20 2015-06-10 韩美科学株式会社 制备特异性位点生理活性多肽结合物的方法
WO2010111414A1 (fr) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Variants du facteur viii et procédés d'utilisation associés
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
WO2011012850A2 (fr) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glyco-polysialylation de protéines de coagulation non sanguine
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
EA025416B1 (ru) 2009-12-06 2016-12-30 Байоджен Хемофилия Инк. Способ предотвращения или лечения эпизодов кровотечений с использованием химерного полипептида фактора viii длительного действия
WO2011075185A1 (fr) 2009-12-18 2011-06-23 Oligasis Conjugués de polymère de phosphorylcholine à médicament ciblé
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
EA201290804A1 (ru) * 2010-02-21 2013-03-29 БАЙЕР ХелсКер ЛЛСи Способ активации и сопряжения биомолекул
SI2558538T1 (sl) 2010-04-15 2019-10-30 Kodiak Sciences Inc Polimeri z visoko relativno molekulsko maso, ki vsebujejo dipolarni ion
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
EP2635297B1 (fr) * 2010-11-05 2019-02-27 Baxalta GmbH Un nouveau variant du facteur viii anti-hémophile ayant une activité spécifique accrue
RU2013131911A (ru) * 2010-12-16 2015-01-27 Ново Нордиск А/С Водный раствор фактора viii
CN103269723B (zh) 2010-12-22 2017-04-05 百深有限责任公司 用于偶联水溶性脂肪酸衍生物与蛋白质的材料和方法
EP3808378A1 (fr) * 2011-05-27 2021-04-21 Baxalta GmbH Protéines thérapeutiques présentant une demi-vie accrue et leurs procédés de préparation
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
US9382305B2 (en) 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
RS58578B1 (sr) 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
HUE046848T2 (hu) 2012-02-15 2020-03-30 Bioverativ Therapeutics Inc VIII. faktor készítmények és eljárások elõállításukra és alkalmazásukra
WO2013120939A1 (fr) 2012-02-15 2013-08-22 Csl Behring Gmbh Variants du facteur de von willebrand ayant une affinité de liaison au facteur viii améliorée
EP2822577B1 (fr) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
EP2666782A1 (fr) 2012-05-22 2013-11-27 Imnate Sarl Facteur VIII de coagulation avec immunogénicité réduite
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
EP3404105A1 (fr) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations
WO2014063108A1 (fr) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Procédés d'utilisation d'une dose fixe d'un facteur de coagulation
WO2014070953A1 (fr) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Procédés d'utilisation du polypeptide fviii
LT2968477T (lt) 2013-03-15 2020-03-10 Bioverativ Therapeutics Inc. Faktoriaus viii polipeptido kompozicijos
RU2015144076A (ru) * 2013-03-15 2017-04-24 БАЙЕР ХелсКер ЛЛСи Композиции рекомбинантного фактора viii
CA2899089C (fr) 2013-03-15 2021-10-26 Biogen Ma Inc. Preparations contenant un polypeptide du facteur ix
CN105307672B (zh) 2013-04-18 2021-01-05 诺和诺德股份有限公司 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
AU2014339034A1 (en) * 2013-10-22 2016-05-19 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
RU2695428C2 (ru) * 2014-01-20 2019-07-23 Октафарма Аг СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag
KR102567586B1 (ko) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
EP3114138B1 (fr) * 2014-03-05 2021-11-17 Pfizer Inc. Mutéines améliorées du facteur viii de coagulation
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
CA2944909A1 (fr) * 2014-04-04 2015-10-08 Bloodworks Laboratoire ordinaire et analyse hors laboratoire de l'hemostase
CA2945390A1 (fr) 2014-04-10 2015-10-15 Bayer Healthcare Llc Formulation de poudre de milieux melanges et procede de preparation de milieu liquide pour la culture cellulaire
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
WO2016000039A1 (fr) 2014-07-02 2016-01-07 Csl Limited Facteur de von willebrand modifié
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3265483B1 (fr) 2015-03-06 2019-12-11 CSL Behring Lengnau AG Facteur de von willebrand modifié présentant une demi-vie améliorée
DK3298036T3 (da) 2015-05-22 2022-06-07 CSL Behring Lengnau AG Fremgangsmåder til forberedelse af modificeret von Willebrand faktor
CA2986626A1 (fr) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Polypeptides du facteur von willebrand tronque pour le traitement de l'hemophilie
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods for their preparation and use
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
SG11201805497QA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
WO2017222330A1 (fr) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Chaîne unique recombinante fviii et son conjugué chimique
CA3043397A1 (fr) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Polypeptides du facteur de von willebrand tronque pour une administration extravasculaire dans le traitement ou la prophylaxie d'un trouble de la coagulation du sang
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
AR110079A1 (es) 2016-11-16 2019-02-20 Bayer Healthcare Llc Factor viii direccionado a los glóbulos rojos y método para su uso
EP3548066A1 (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
EP3548063A1 (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Procédés d'induction de tolérance immunitaire à des facteurs de coagulation
CN110831613A (zh) 2017-01-31 2020-02-21 比奥维拉迪维治疗股份有限公司 因子ix融合蛋白及其制备和使用方法
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
US20190375822A1 (en) 2018-05-18 2019-12-12 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
WO2021072265A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
WO2021091881A1 (fr) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York Compositions de conjugués d'inhibiteurs de caspase de pénétration cellulaire à concentration élevée et procédés associés
CN114828870A (zh) * 2019-12-06 2022-07-29 费城儿童医院 用于调节因子viii功能的组合物和方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
EP0690126B1 (fr) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Protéines à activité de facteur VIII, procédé pour leur production utilisant des cellules modifiées par génie génétique et compositions pharmaceutiques les contenant
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1994007510A1 (fr) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprenant une formulation d'un facteur de coagulation viii, procede pour sa preparation et utilisation d'un agent tensioactif comme stabilisateur
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU685187B2 (en) 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
CA2204726A1 (fr) 1994-11-09 1996-12-27 Robin E. Offord Polymeres fonctionnalises destines a une ligation dirigee
AU691111B2 (en) * 1995-06-21 1998-05-07 Google Technology Holdings LLC Method and antenna for providing an omnidirectional pattern
WO1997003195A1 (fr) 1995-07-11 1997-01-30 Chiron Corporation Nouveaux analogues polypeptidiques de facteur viii:c ayant des sites de protease modifies
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
KR20000029673A (ko) * 1996-08-02 2000-05-25 오르토-맥네일 파마슈티칼, 인코퍼레이티드 단일의공유결합된ｎ-말단수용성폴리머를갖는폴리펩티드
CA2225189C (fr) 1997-03-06 2010-05-25 Queen's University At Kingston Gene et proteine du facteur viii du chien et methodes d'utilisation
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU751898B2 (en) 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
CN1113656C (zh) * 1997-10-17 2003-07-09 丰收技术股份有限公司 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物
EP0922446A1 (fr) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site
ATE283034T1 (de) 1998-04-27 2004-12-15 Opperbas Holding Bv Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
ES2292255T5 (es) 1998-11-10 2017-05-19 Stichting Sanquin Bloedvoorziening Polipéptido del factor 8 con actividad de factor 8:C
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
ES2373093T3 (es) 1999-01-14 2012-01-31 Bolder Biotechnology, Inc. Métodos para preparar proteínas que contienen restos de cisteína libres.
WO2000071714A2 (fr) 1999-05-24 2000-11-30 The American National Red Cross Procedes de reduction de la clairance du facteur viii et compositions correspondantes
US6806063B2 (en) * 2000-02-11 2004-10-19 Maxygen Aps Factor VII or VIIa-like molecules
WO2002024723A1 (fr) 2000-09-19 2002-03-28 Emory University Facteur viii modifie
WO2002060951A2 (fr) 2001-01-12 2002-08-08 The American National Red Cross Methodes et compositions permettant de reduire la clairance du facteur viii, mediee par l'heparan-sulfate proteoglycane
AU2002249096B2 (en) * 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
AU2002312660A1 (en) 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (fr) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Molecules recombinees avec immunogenicite reduite, procedes et intermediaires permettant d'obtenir ces molecules, et utilisation de ces molecules dans des compositions pharmaceutiques et des outils diagnostiques
DE60234193D1 (de) 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
CA2461443C (fr) 2001-10-05 2011-07-12 Emory University Sequences d'acides nucleiques et d'acides amines codant des polypeptides de facteur viii a expresseur a haut rendement et leurs procedes d'utilisation
MXPA04010061A (es) 2002-04-18 2004-12-13 Merck Patent Gmbh Factor viii modificado.
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
DE60321825D1 (de) 2002-12-31 2008-08-07 Nektar Therapeutics Al Corp Maleinsäureamid polymerderivate und ihre biokonjugate
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
US7910661B2 (en) 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
KR101085375B1 (ko) * 2003-02-26 2011-11-21 넥타르 테라퓨틱스 중합체-인자 ⅷ 부분 콘쥬게이트
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
BRPI0411160A (pt) * 2003-05-12 2006-07-11 Affymax Inc novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
EP1502921A1 (fr) 2003-07-29 2005-02-02 ZLB Behring GmbH Mutants du Facteur VIII (FVIII) humain recombinants ayant une meilleure stabilité
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ATE463572T1 (de) 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2006027111A1 (fr) 2004-09-06 2006-03-16 Zlb Behring Gmbh Facteur viii de coagulation modifie presentant une meilleure stabilite
PL2371856T3 (pl) 2004-11-12 2022-08-22 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
JP2008534559A (ja) 2005-04-01 2008-08-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 血液凝固ｆｖｉｉｉ類似体
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CA2647314A1 (fr) 2006-03-31 2007-11-08 Baxter International Inc. Facteur viii pegyle

Also Published As

Publication number Publication date
EP2371856B1 (fr) 2022-05-18
EP3243834A1 (fr) 2017-11-15
JP6109523B2 (ja) 2017-04-05
LT3130601T (lt) 2020-09-10
LUC00118I1 (fr) 2019-05-13
MA29663B1 (fr) 2008-08-01
KR101483917B1 (ko) 2015-01-16
EP2371856A2 (fr) 2011-10-05
PT2363414T (pt) 2022-08-04
MX2007005466A (es) 2007-10-19
UA95225C2 (ru) 2011-07-25
AU2005304622B2 (en) 2012-03-29
LT2363414T (lt) 2022-10-25
KR20140019489A (ko) 2014-02-14
NO345800B1 (no) 2021-08-09
HUS1900026I1 (hu) 2022-04-28
IL232540A (en) 2017-08-31
CN103102406B (zh) 2015-05-27
JP2017101028A (ja) 2017-06-08
HUE059193T2 (hu) 2022-10-28
EP1824988A4 (fr) 2008-12-31
CY2019024I1 (el) 2019-11-27
WO2006053299A2 (fr) 2006-05-18
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
EP2371856A3 (fr) 2012-03-14
EP3130601B1 (fr) 2020-07-15
NL300989I2 (nl) 2019-11-28
SI2371856T1 (sl) 2022-09-30
BRPI0517795A (pt) 2008-10-21
KR20140091618A (ko) 2014-07-21
EP3130601A1 (fr) 2017-02-15
EP2772500A1 (fr) 2014-09-03
RU2423380C2 (ru) 2011-07-10
ES2930159T3 (es) 2022-12-07
JP2015134780A (ja) 2015-07-27
EP3323829A1 (fr) 2018-05-23
IL234433B (en) 2019-11-28
KR101654011B1 (ko) 2016-09-05
DK2371856T3 (en) 2022-08-08
HRP20070268B1 (hr) 2018-04-20
PT2371856T (pt) 2022-08-12
KR101243564B1 (ko) 2013-03-27
ZA200703696B (en) 2008-08-27
NO344606B1 (no) 2020-02-10
HK1218718A1 (zh) 2017-03-10
US20060115876A1 (en) 2006-06-01
PH12014500352B1 (en) 2015-07-20
PT3130601T (pt) 2020-10-01
HRP20070268A2 (en) 2007-09-30
ES2930143T3 (es) 2022-12-07
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
HUE033776T2 (en) 2018-01-29
DK1824988T3 (en) 2017-08-07
JP6559642B2 (ja) 2019-08-14
US9364520B2 (en) 2016-06-14
EP3243833B1 (fr) 2020-06-17
KR20130036780A (ko) 2013-04-12
JP2008524117A (ja) 2008-07-10
BRPI0517795A8 (pt) 2018-12-26
LT2371856T (lt) 2022-08-25
EP3243833A1 (fr) 2017-11-15
EP2363414A3 (fr) 2012-03-21
RU2007121517A (ru) 2008-12-20
SI3130601T1 (sl) 2020-11-30
PL2363414T3 (pl) 2022-09-05
KR20160105928A (ko) 2016-09-07
AU2005304622A1 (en) 2006-05-18
US20130274445A1 (en) 2013-10-17
CN101124331B (zh) 2013-04-24
FR19C1031I2 (fr) 2020-06-05
HRP20180481A2 (hr) 2018-06-29
JP6487895B2 (ja) 2019-03-20
US20100081615A1 (en) 2010-04-01
NO20200044A1 (no) 2007-06-27
BRPI0517795B1 (pt) 2020-03-31
PH12014500352A1 (en) 2015-07-20
US7632921B2 (en) 2009-12-15
EP1824988B1 (fr) 2017-04-19
HN2007015683A (es) 2011-07-11
CN105753968A (zh) 2016-07-13
HK1182121A1 (en) 2013-11-22
PL1824988T3 (pl) 2018-01-31
EP2363414A2 (fr) 2011-09-07
HK1117875A1 (en) 2009-01-23
LTC1824988I2 (lt) 2021-02-25
JP2017105773A (ja) 2017-06-15
KR101904630B1 (ko) 2018-10-04
IL232540A0 (en) 2014-06-30
EP3323829B1 (fr) 2020-07-15
BR122016022033B8 (pt) 2021-05-25
FR19C1031I1 (fr) 2019-06-28
EP1824988A2 (fr) 2007-08-29
HRP20180481B1 (hr) 2022-02-18
NZ555032A (en) 2010-02-26
NL300989I1 (nl) 2019-05-22
CN103214569B (zh) 2016-12-28
KR101468345B1 (ko) 2014-12-03
DK2363414T3 (da) 2022-08-08
NO20072997L (no) 2007-06-27
LT1824988T (lt) 2017-10-25
CN103214569A (zh) 2013-07-24
KR20180110192A (ko) 2018-10-08
CN105148287A (zh) 2015-12-16
CN103102406A (zh) 2013-05-15
EP3153181A1 (fr) 2017-04-12
BRPI0517795B8 (pt) 2021-05-25
CA2586379C (fr) 2012-04-03
MX350293B (es) 2017-09-04
US9096656B2 (en) 2015-08-04
LTPA2019509I1 (lt) 2019-08-26
EP2363414B1 (fr) 2022-05-18
EP2772500B1 (fr) 2019-12-25
CY1123384T1 (el) 2021-12-31
CN101124331A (zh) 2008-02-13
US20160051633A1 (en) 2016-02-25
CY1119292T1 (el) 2018-02-14
JP2013067621A (ja) 2013-04-18
IL182903A0 (en) 2007-08-19
SI1824988T1 (sl) 2017-11-30
ES2633916T3 (es) 2017-09-26
HUE050542T2 (hu) 2020-12-28
BR122016022033B1 (pt) 2021-03-02
CN105148287B (zh) 2019-07-09
WO2006053299A3 (fr) 2006-08-24
IL182903A (en) 2014-09-30
HUE060016T2 (hu) 2023-01-28
CA2586379A1 (fr) 2006-05-18
KR20120136413A (ko) 2012-12-18
PT1824988T (pt) 2017-07-21
ES2821832T3 (es) 2021-04-27
PH12019501613A1 (en) 2020-09-14
CN107082806A (zh) 2017-08-22
CY2019024I2 (el) 2019-11-27
PL2371856T3 (pl) 2022-08-22

Similar Documents

Publication Publication Date Title
LUC00118I2 (fr)
BE2015C038I2 (fr)
BRPI0518216C1 (fr)
BRPI0515516B8 (fr)
BR122015024347A2 (fr)
BRPI0508002A (fr)
JP2005029259A5 (fr)
BR122018073034B8 (fr)
BRPI0508029A (fr)
BRPI0419105B8 (fr)
BRPI0508026A (fr)
JP2006026229A5 (fr)
BRPI0508033A (fr)
AT501137B8 (fr)
CN300731631S (zh) 衣架
CN300736471S (zh) 抽水马桶
CN300747428S (zh) 便携式电子商品监测系统
CN300756230S (zh) 包装纸盒
CN300781317S (zh) 叉车
CN300781624S (zh) 电视机
CN300742588S (zh) 洗手盆
CN300742685S (zh) 建筑用梁
CN300765107S (zh) 椅子
CN300779224S (zh) 龙头
CN300736472S (zh) 洗手盆